Methods for Measuring Insulin Sensitivity

NCT00001625 | Completed

• 2 other identifiers: 97010597-AT-0105
• Study Type: observational
• Target: 480
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with high blood pressure, diabetes, and who are overweight are known to have defects in the way their body responds to insulin. The purpose of this study is to develop better methods for measuring the way body tissue responds to insulin and sugar (glucose). Researchers are planning to study four groups of patients.

1. 1.Normal volunteers
2. 2.Patients who have mild to moderate high blood pressure
3. 3.Patients who are overweight
4. 4.Patients who have mild to moderate diabetes controlled with oral medication

Conditions

Obesity; Hypertension; Diabetes-Mellitus, Non-Insulin Dependent

Keywords

Insulin Resistance; Obesity; Hypertension; Diabetes; Mathematical Modeling; Normal Volunteer

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Normal Volunteers:
• Adults between the ages of 21 and 55 in good general health with no significant underlying illnesses, on no medication, and a normal body mass index (20-26 kg/m(2)).
• Obese Subjects:
• Adults between the ages of 21 and 55 in good general health with no significant underlying illnesses, on no medication, and a body mass index between 30 and 35 kg/m(2).
• Hypertensive Subjects:
• Adults between the ages of 21 and 55 in good general health except for mild to moderate hypertension (blood pressure between 140/95 and 170/109 off medication), on no medication except for antihypertensive agents.
• Subjects will be taken off all antihypertensive drugs for at least one week prior to study. If a subjects blood pressure exceeds 180/110 on three determinations over a period of at least 15 minutes, the subject will be withdrawn from the study and appropriate antihypertensive therapy resumed.
• Diabetic Subjects:
• Adults between the ages of 21 and 65 in good general health except for non-insulin dependent diabetes mellitus controlled with oral hypoglycemic agents. Subjects on no other medications. If fasting blood glucose exceeds 300 mg/dl, the subject will be withdrawn from the study and appropriate therapy resumed.

You may not qualify if:

• Pregnancy, liver disease, pulmonary disease, end-organ damage such as renal insufficiency, coronary artery disease, heart failure, peripheral vascular disease, proliferative retinopathy, diabetic neuropathy, or HIV infection.

Sponsors & Collaborators

• National Center for Complementary and Integrative Health (NCCIH): lead
• Office of Dietary Supplements (ODS): collaborator

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (1)

• Quon MJ, Cochran C, Taylor SI, Eastman RC. Non-insulin-mediated glucose disappearance in subjects with IDDM. Discordance between experimental results and minimal model analysis. Diabetes. 1994 Jul;43(7):890-6. doi: 10.2337/diab.43.7.890.

  PMID: 8013753 BACKGROUND

MeSH Terms

Conditions

Obesity; Hypertension; Diabetes Mellitus, Type 2; Insulin Resistance; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Vascular Diseases; Cardiovascular Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Hyperinsulinism

Study Design

• Study Type: observational
• Sponsor Type: NIH

Study Record Dates

• First Submitted: November 3, 1999
• First Posted: November 4, 1999
• Study Start: April 3, 1997
• Study Completion: April 11, 2007
• Last Updated: July 2, 2017

Record last verified: 2007-04-11

Locations

US (1)